Equities

PYC Therapeutics Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

PYC Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)1.50
  • Today's Change-0.005 / -0.33%
  • Shares traded642.70k
  • 1 Year change+19.12%
  • Beta0.6841
Data delayed at least 20 minutes, as of Feb 09 2026 05:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy0
Outperform5
Hold0
Sell0
Strong Sell0

Share price forecast in AUD

The 5 analysts offering 12 month price targets for PYC Therapeutics Ltd have a median target of 3.88, with a high estimate of 4.96 and a low estimate of 2.25. The median estimate represents a 159.53% increase from the last price of 1.50.
High231.8%4.96
Med159.5%3.88
Low50.2%2.25

Earnings history & estimates in AUD

PYC Therapeutics Ltd reported annual 2025 losses of -0.099 per share on Aug 28, 2025.
Average growth rate-545.04%
More ▼

Revenue history & estimates in AUD

PYC Therapeutics Limited had revenues for the full year 2025 of 26.17m. Last year the company did not report any revenues.
Average growth rate+489.02%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.